LEXEO
Live / Applied — Second extension granted (statement of use) (as of 31 Mar 2026)
What this means for you
Not registered yet, but its 04 Oct 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98209814
- Mark type
- Stylized text
- Filed
- 04 Oct 2023
- Published for opposition
- 04 Feb 2025
- Attorney of record
- Elizabeth A. Walker
Goods and services
- Class 005 — Pharmaceuticals: House mark for the following, namely, Pharmaceutical preparations for the treatment of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Friedreich's Ataxia; Pharmaceutical preparations for the treatment of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the treatment of hypertrophic cardiomyopathy; Pharmaceutical preparations for the treatment of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the treatment of Alzheimer's disease; Pharmaceutical preparations for the treatment of Batten disease; Pharmaceutical preparations for the treatment of genetic diseases, disorders, and defects; Pharmaceutical preparations for the treatment of monogenic diseases, disorders, and defects; Biologic gene therapy preparations for the treatment of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for targeting underlying causes of diseases, disorders, and defects for treatment therefor; Therapeutic agents for delivery of genetically engineered viruses to patients for treatment of diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of cardiovascular diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of Friedreich's Ataxia; Pharmaceutical preparations for the detection or diagnosis of arrhythmogenic cardiomyopathy; Pharmaceutical preparations for the detection or diagnosis of hypertrophic cardiomyopathy; Pharmaceutical preparations for the detection or diagnosis of central nervous system diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of Alzheimer's disease; Pharmaceutical preparations for the detection or diagnosis of Batten disease; Pharmaceutical preparations for the detection or diagnosis of genetic diseases, disorders, and defects; Pharmaceutical preparations for the detection or diagnosis of monogenic diseases, disorders, and defects; Biologic gene therapy preparations for the detection or diagnosis of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for detection or diagnosis of underlying causes of diseases, disorders, and defects; Therapeutic agents for delivery of genetically engineered viruses to patients for detection or diagnosis of diseases, disorders, and defects
Owner
- Lexeo Therapeutics, Inc., New York, NY, US
- Lexeo Therapeutics, Inc., New York, NY, US
Prosecution history
- 02 Apr 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 31 Mar 2026 — SOU EXTENSION 2 GRANTED
- 30 Mar 2026 — SOU EXTENSION 2 FILED
- 30 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 08 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 30 Sept 2025 — SOU EXTENSION 1 GRANTED
- 30 Sept 2025 — SOU EXTENSION 1 FILED
- 30 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 01 Apr 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 04 Feb 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 04 Feb 2025 — PUBLISHED FOR OPPOSITION
- 29 Jan 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 15 Jan 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 15 Jan 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 15 Jan 2025 — NON-FINAL ACTION E-MAILED